[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549803":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":18,"responsibleParty":25,"collaborators":18,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":18,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":18,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":18,"overallStatus":48,"whyStopped":18,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":18},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Blinatumomab group","EXPERIMENTAL","Blinatumomab group (Blinatumomab): 9 μg\u002Fd intravenously over 24 hours until the end of d14 days of dosing. Repeat every 3 months for a total of 4 courses. (Basis for Dose Selection: The recommended dose of blinatumomab for MRD-negative patients is 9ug\u002Fd)",[13],"Drug: Blinatumomab",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Maintenance therapy in the control group was based on the routine maintenance therapy in each center (including but not limited to decitabine, sorafenib, prophylactic DLI, except for all types of CD19 mono- and dual-antibodies and CD22-ADC drugs).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Blinatumomab","Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation",[9],{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Hu Xiaoxia","Principal Investigator","100549803","phase-2-blinatumomab-maintenance-after-allo-hsct-100549803",false,"NCT06438796","Blinatumomab Maintenance After Allo-HSCT","Efficacy and Safety of Blinatumomab Maintenanceafter Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Acute B-lymphoblastic Leukemia: a Multicenter, Open-label, Randomized Controlled Study","Inclusion Criteria:\n\n1. Age 16-65 years\n2. Diagnosis with acute B-lymphoblastic leukemia (B-ALL) expressed CD19\n3. High-risk group B-ALL\n4. Have suitable hematopoietic stem cell donors\n5. No dysfunction of vital organs\n\nExclusion Criteria:\n\n1. CR\u002FMRD negative before blinatumomab maintenance\n2. Active hepatitis B\n3. HIV-infected\n4. Active infections; acute and chronic GVHD requiring systemic immunosuppressive therapy;\n5. severe impairment of vital organ function\n6. Those judged by the investigator to be unsuitable for participation in this trial.","ALL","16 Years","65 Years",{"count":40,"type":41},59,"ESTIMATED","INTERVENTIONAL",[44],"PHASE2","To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.",[47],"High Risk Acute Lymphoblastic Leukemia","NOT_YET_RECRUITING","2024-05-30",{"date":51,"type":52},"2024-06-03","ACTUAL",{"date":54,"type":41},"2024-07-01",{"date":56,"type":41},"2028-07-01",{"name":5,"class":6}]